All In Biotech

Drug Trial Radar · NCT07688213

A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 48-week SAR448851 Treatment Followed by Open-label Extension in Participants With Early Alzheimer's Disease

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Jul 28, 2026

Primary completion

Jul 31, 2029

Study completion Jul 31, 2029

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Jul 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 55 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, placebo-controlled Phase 2 study to evaluate the efficacy and safety of SAR448851 in early Alzheimer's disease (AD) participants. The purpose of this study is to measure efficacy and safety with once daily oral SAR448851 compared to placebo in participants with mild cognitive impairment due to AD or mild AD dementia and with evidence of cerebral amyloid pathology. This Phase 2 study has 2 parts: Part A is a randomized, double-blind, parallel-group, placebo-controlled study with SAR448851 oral once daily. Part B is an open-label extension. All participants who complete Part A may continue to Part B. An optional dose 2 cohort will be considered to evaluate the efficacy and safety of SAR448851 dose 2 oral once daily. The study duration will be up to 111 weeks for Part A and B, and up to 63 weeks for the dose 2 cohort. The treatment duration will be up to 96 weeks for Part A and B, and up to 48 weeks for the dose 2 cohort. Up to 160 participants will be included in this study.

Conditions

  • Dementia, Alzheimer's Type
  • Alzheimer's Disease

Interventions

  • SAR448851Drug

    Pharmaceutical form: Capsule Route of administration: Oral

  • PlaceboDrug

    Pharmaceutical form: Capsule Route of administration: Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A and optional dose 2 cohort: change from baseline to Week 48 in plasma p-tau217Time frame: From baseline to Week 48
  2. Part B: Number of participants with treatment-emergent adverse events (TEAE), including ARIA-E and ARIA-H by brain MRI, laboratory assessments, vital sign measurements, ECGs and the C-SSRSTime frame: From Week 48 to Week 96

Locations

32 sites in 7 countries. Site status is shown where the registry gives one.

  • Healthy Brain Clinic- Site Number : 8400011

    Long Beach, California · Recruiting

  • Oakland Clinical- Site Number : 8400010

    Oakland, California · Recruiting

  • Aqualane Clinical Research- Site Number : 8400001

    Naples, Florida · Recruiting

  • K2 Medical Research - Orlando - South Orlando Avenue- Site Number : 8400008

    Orlando, Florida · Recruiting

  • Alzheimer's Research and Treatment Center - Stuart, FL- Site Number : 8400014

    Stuart, Florida · Recruiting

  • Axiom Brain Health- Site Number : 8400019

    Tampa, Florida · Recruiting

  • Charter Research - Lady Lake- Site Number : 8400004

    The Villages, Florida · Recruiting

  • Alzheimer's Research and Treatment Center - Wellington- Site Number : 8400012

    Wellington, Florida · Recruiting

  • Boston Center for Memory - Newton- Site Number : 8400007

    Newton, Massachusetts · Recruiting

  • The Cognitive and Research Center of New Jersey - Springfield- Site Number : 8400005

    Springfield, New Jersey · Recruiting

  • Summit Research Network - Portland - Northwest Vaughn Street- Site Number : 8400002

    Portland, Oregon · Recruiting

  • Flourish Research - Keystone Clinical Studies- Site Number : 8400003

    Plymouth Meeting, Pennsylvania · Recruiting

  • Rhode Island Mood & Memory Research Institute- Site Number : 8400015

    East Providence, Rhode Island · Recruiting

  • Kerwin Medical Center- Site Number : 8400006

    Dallas, Texas · Recruiting

  • Investigational Site Number : 0360001

    Macquarie Park, New South Wales, Australia · Recruiting

  • Investigational Site Number : 0360003

    Ivanhoe, Victoria, Australia · Recruiting

  • Investigational Site Number : 0360004

    Melbourne, Victoria, Australia · Recruiting

  • Investigational Site Number : 1240001

    Ottawa, Ontario, Canada · Recruiting

  • Investigational Site Number : 1240005

    Toronto, Ontario, Canada · Recruiting

  • Investigational Site Number : 1240008

    Montreal, Quebec, Canada · Recruiting

  • Investigational Site Number : 1560001

    Beijing, China · Recruiting

  • Investigational Site Number : 2760003

    Berlin, Germany · Recruiting

  • Investigational Site Number : 2760002

    Cologne, Germany · Recruiting

  • Investigational Site Number : 7240001

    Valencia, Spain · Recruiting

  • Investigational Site Number : 7240005

    Zaragoza, Spain · Recruiting

  • Investigational Site Number : 7240008

    Barcelona, Barcelona [Barcelona], Spain · Recruiting

  • Investigational Site Number : 7240006

    Barcelona, Barcelona [Barcelona], Spain · Recruiting

  • Investigational Site Number : 7240004

    Barcelona, Catalunya [Cataluña], Spain · Recruiting

  • Investigational Site Number : 7240003

    Pozuelo de Alarcón, Madrid, Spain · Recruiting

  • Investigational Site Number : 8260002

    London, Hammersmith and Fulham, United Kingdom · Recruiting

  • Investigational Site Number : 8260001

    London, London, City of, United Kingdom · Recruiting

  • Investigational Site Number : 8260004

    Bath, Somerset, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.